St. Jude Clinical Trials
CATCHAML: CAR T-Cell Therapy for Acute Myelogenous Leukemia (AML)
CATCHAML: CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia
Diseases Treated:
Acute Myelogenous Leukemia
Eligibility:
- 21 years old or younger
- Relapsed/refractory CD123+ AML, B-ALL, T-ALL or blastic plasmacytoid dendritic cell neoplasm
- Has a suitable bone marrow transplant donor for allogeneic bone marrow transplant
CPXSMN: CPX-351 in Pediatric Patients with Secondary Myeloid Neoplasms
A Prospective, Multicenter, Single-Arm Pilot Study of CPX-351 (VYXEOS) in Individuals < 22 Years with Secondary Myeloid Neoplasms
Diseases Treated:
Eligibility:
- 1–22 years old
- Treatment-related or secondary MDS/AML
HAP2HCT: Partially Matched Family Donor Bone Marrow Transplant in Children and Young Adults with High Risk Cancer
TCRαβ-depleted Progenitor Cell Graft with Additional Memory T-Cell DLI, plus Selected Use of Blinatumomab, in Naïve T-Cell depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies
Diseases Treated:
- Acute lymphoblastic leukemia
- Acute myeloid leukemia
- Myelodysplasia
- Hodgkin lymphoma
- Non-Hodgkin lymphoma
- Juvenile myelomonocytic leukemia
Eligibility:
For transplant recipient:
- 21 years or younger
- Does not have a suitable sibling donor or volunteer unrelated donor
- Has a suitable single haplotype matched family member donor
- Diagnosed with high risk hematologic malignancy
- No prior allogeneic hematopoietic cell transplant
HAPNK1: Blood and Marrow Transplant (BMT) for Children with Leukemia/Lymphoma
Haploidentical Donor Hematopoietic Progenitor Cell and Natural Killer Cell Transplantation with a TLI-Based Conditioning Regimen in Patients with Hematologic Malignancies
Diseases Treated:
Eligibility:
- 21 years and younger
- Does not have a suitable HLA-matched sibling donor or volunteer HLA-matched unrelated donor or is not a candidate for conventional matched donor transplant due to refractory disease
- Has a suitable single haplotype-matched family member donor
- High-risk hematologic malignancy, including certain diagnoses of:
- Acute lymphoblastic leukemia (ALL)
- Acute myeloid leukemia (AML)
- Chronic myelogenous leukemia (CML)
- Myelodysplastic syndrome (MDS)
- Hodgkin lymphoma
- Non-Hodgkin lymphoma
INOMRD: Inotuzumab Ozogamicin for Children with High-Risk B-Cell ALL
Inotuzumab Ozogamicin for Children with MRD Positive CD22+ Acute Lymphoblastic Leukemia
Diseases Treated:
Eligibility:
- Younger than 22 years old
- Diagnosis of B-cell acute lymphoblastic leukemia (B-ALL) with minimal residual disease (MRD) between 0.1 and 4.99% after prior chemotherapy, relapse or stem cell transplant
MEMCAR19: Allogeneic CAR T-Cell Therapy for Relapsed/Refractory CD19-Positive Leukemia
Phase I Study Evaluating Allogeneic Memory T Cells Engineered to Express Chimeric Antigen Receptors Specific for CD19 for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory CD19-positive Leukemia
Diseases Treated:
Eligibility:
Donor eligibility includes:
- At least 18 years old
- At least single haplotype matched family member
- HIV negative
- Not pregnant or breastfeeding
Recipient eligibility includes:
- 21 years old or younger*
- Diagnosed with relapsed and/or refractory CD19-positive leukemia
- Cohort A only – Relapsed and/or refractory CD19-positive leukemia AND previously received a hematopoietic cell transplant from the selected CAR-T donor
- Cohort B only: Can not receive autologous CD19-CAR T-cell therapy (per study)
- Detectable medullary leukemia
* Initial 3 participants must be at least 16 years old.
RAVEN: Clinical Trial to Treat Relapsed Acute Lymphoblastic Leukemia with Venetoclax and Navitoclax
A Phase I/II Trial Treating Relapsed Acute Lymphoblastic Leukemia with Venetoclax and Navitoclax
Diseases Treated:
Acute Lymphoblastic Leukemia and Lymphoma
Eligibility:
- Diagnosed with relapsed or refractory acute lymphoblastic leukemia or lymphoma
- Between 4 and 22 years old
- Weigh more than 20 kg (44.09 lbs.)
- Able to swallow pills
- No prior exposure to navitoclax
- Fully recovered from effects of any prior treatment
REF2HCT: Haploidentical Bone Marrow Transplant for Leukemia and Lymphoma
Provision of TCRγδ T Cells and Memory T Cells plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory despite Prior Transplantation
Diseases Treated:
Eligibility:
- 21 years old and younger
- Diagnosed with one of the following that has come back or did not improve after bone marrow transplant
- Acute lymphoblastic leukemia (ALL)
- Acute myeloid leukemia
- Myeloid sarcoma
- Chronic myeloid leukemia (CML)
- Juvenile myelomonocytic leukemia (JMML)
- Myelodysplastic syndrome (MDS)
- Non-Hodgkin lymphoma (NHL)
- Has a family member who is a suitable stem cell donor
SJCAR19: CAR T-Cell Therapy for Children and Young Adults with Acute Lymphoblastic Leukemia
A Phase I/II Study Evaluating CD19-Specific CAR Engineered Autologous T-Cells in Pediatric and Young Adult Patients with Relapsed or Refractory CD19+ Acute Lymphoblastic Leukemia
Diseases Treated:
Eligibility:
- Children and young adults up to 21 years old
- Refractory or relapsed CD19+ acute lymphoblastic leukemia (ALL)
Collaborative Clinical Trials
APAL2020D: Venetoclax in Children with Relapsed Acute Myeloid Leukemia (AML)
A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamicin With or Without Venetoclax in Children With Relapsed AML
Diseases Treated:
Eligibility:
- Diagnosis of relapsed acute myeloid leukemia (AML)
- Ages 29 days old to 21 years old
- Have had AML come back for the first or second time
- May have heart problems that prevent them from taking anthracyclines